[go: up one dir, main page]

AU2738497A - Omega-3 fatty acids and omega-3 phosphatidylcholine in the treatment of bipolar disorder - Google Patents

Omega-3 fatty acids and omega-3 phosphatidylcholine in the treatment of bipolar disorder

Info

Publication number
AU2738497A
AU2738497A AU27384/97A AU2738497A AU2738497A AU 2738497 A AU2738497 A AU 2738497A AU 27384/97 A AU27384/97 A AU 27384/97A AU 2738497 A AU2738497 A AU 2738497A AU 2738497 A AU2738497 A AU 2738497A
Authority
AU
Australia
Prior art keywords
omega
phosphatidylcholine
treatment
fatty acids
bipolar disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU27384/97A
Inventor
Wolfram E. Severus
Andrew L. Stoll
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brigham and Womens Hospital Inc
Original Assignee
Brigham and Womens Hospital Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham and Womens Hospital Inc filed Critical Brigham and Womens Hospital Inc
Publication of AU2738497A publication Critical patent/AU2738497A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/10—Phosphatides, e.g. lecithin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU27384/97A 1996-04-24 1997-04-23 Omega-3 fatty acids and omega-3 phosphatidylcholine in the treatment of bipolar disorder Abandoned AU2738497A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1614096P 1996-04-24 1996-04-24
US60016140 1996-04-24
PCT/US1997/006712 WO1997039759A2 (en) 1996-04-24 1997-04-23 Omega-3 fatty acids and omega-3 phosphatidylcholine in the treatment of bipolar disorder

Publications (1)

Publication Number Publication Date
AU2738497A true AU2738497A (en) 1997-11-12

Family

ID=21775605

Family Applications (1)

Application Number Title Priority Date Filing Date
AU27384/97A Abandoned AU2738497A (en) 1996-04-24 1997-04-23 Omega-3 fatty acids and omega-3 phosphatidylcholine in the treatment of bipolar disorder

Country Status (2)

Country Link
AU (1) AU2738497A (en)
WO (1) WO1997039759A2 (en)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6852870B2 (en) 1999-03-22 2005-02-08 Andrew Stoll Omega-3 fatty acids in the treatment of depression
GB9901809D0 (en) * 1999-01-27 1999-03-17 Scarista Limited Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
AU2006201772B2 (en) * 1999-01-27 2010-02-04 Amarin Neuroscience Limited Highly purified ethyl EPA and other EPA derivatives for psychiatric and neurological disorders
GB9901808D0 (en) * 1999-01-27 1999-03-17 Scarista Limited Drugs for treatment of psychiatric and brain disorders
US7208180B2 (en) * 2000-05-08 2007-04-24 N.V. Nutricia Method and preparation for the preventing and/or treating vascular disorders and secondary disorders associated therewith
US7226916B1 (en) 2000-05-08 2007-06-05 N.V. Nutricia Preparation for the prevention and/or treatment of vascular disorders
DK1417211T3 (en) 2001-07-27 2007-10-08 Neptune Technologies & Bioress Natural marine phospholipids containing flavonoids and polyunsaturated phospholipids and their use
US7935365B2 (en) 2003-10-22 2011-05-03 Enzymotec, Ltd. Glycerophospholipids for the improvement of cognitive functions
IL158552A0 (en) * 2003-10-22 2004-05-12 Enzymotec Ltd Lipids containing omega-3 fatty acids
US20050130937A1 (en) 2003-10-22 2005-06-16 Enzymotec Ltd. Lipids containing omega-3 and omega-6 fatty acids
US8052992B2 (en) 2003-10-22 2011-11-08 Enzymotec Ltd. Glycerophospholipids containing omega-3 and omega-6 fatty acids and their use in the treatment and improvement of cognitive functions
US20140343143A1 (en) * 2004-01-21 2014-11-20 Tiberio Bruzzese Use of highly concentrated compositions of selected n-3 fatty acids for the treatment of central nervous system disturbances
GB2421909A (en) * 2004-12-23 2006-07-12 Laxdale Ltd Pharmaceutical compositions comprising EPA and methods of use
US8697138B2 (en) 2007-03-28 2014-04-15 Aker Biomarine As Methods of using krill oil to treat risk factors for cardiovascular, metabolic, and inflammatory disorders
US9034388B2 (en) 2007-03-28 2015-05-19 Aker Biomarine Antartic As Bioeffective krill oil compositions
ATE554775T1 (en) * 2007-11-16 2012-05-15 Baylor College Medicine PHOSPHOLIPID COMPOSITIONS AND USES THEREOF
US20110236476A1 (en) 2008-09-02 2011-09-29 Amarin Corporation Plc. Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same
PT3037089T (en) 2009-02-10 2020-03-04 Amarin Pharmaceuticals Ie Ltd Eicosapentaenoic acid ethyl ester for treating hypertriglyceridemia
US8372812B2 (en) 2009-02-26 2013-02-12 Aker Biomarine Asa Phospholipid and protein tablets
WO2010127099A2 (en) 2009-04-29 2010-11-04 Amarin Corporation Plc Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
SG10201605794PA (en) 2009-04-29 2016-09-29 Amarin Pharmaceuticals Ie Ltd Stable Pharmaceutical Composition And Methods Of Using Same
CN108096209A (en) 2009-06-15 2018-06-01 阿马里纳制药公司 Triglycerides, composition and method without increasing LDL-C levels are reduced in the object of associated Statins therapy
WO2011038122A1 (en) 2009-09-23 2011-03-31 Amarin Corporation Plc Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
NZ600167A (en) 2009-10-29 2014-06-27 Acasti Pharma Inc Concentrated therapeutic phospholipid compositions
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
EP2646013A4 (en) 2010-11-29 2014-03-26 Amarin Pharma Inc LOW-ERUCATION COMPOSITION AND METHODS FOR TREATING AND / OR PREVENTING CARDIOVASCULAR DISEASE IN A SUBJECT HAVING FISH ALLERGY / HYPERSENSITIVITY
US20140315786A1 (en) * 2011-03-18 2014-10-23 Catabasis Pharmaceuticals, Inc. Use of intracellular enzymes for the release of covalently linked bioactives
US8846604B2 (en) 2011-09-02 2014-09-30 Artic Nutrition AS Lipid compositions with high DHA content
EP2775837A4 (en) 2011-11-07 2015-10-28 Amarin Pharmaceuticals Ie Ltd Methods of treating hypertriglyceridemia
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
PT2800563T (en) 2012-01-06 2018-11-07 Chrysalis Pharma Ag Dpa-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form
JP6307442B2 (en) 2012-01-06 2018-04-04 アマリン ファーマシューティカルス アイルランド リミテッド Compositions and methods for reducing the level of high sensitivity (HS-CRP) in a subject
US20130295173A1 (en) 2012-05-07 2013-11-07 Omthera Pharmaceuticals, Inc. Compositions of statins and omega-3 fatty acids
SMT202500326T1 (en) 2012-06-29 2025-11-10 Amarin Pharmaceuticals Ie Ltd Eicosapentaenoic acid ethyl ester for use in reducing the risk of non-fatal stroke in a subject on statin therapy
US20150265566A1 (en) 2012-11-06 2015-09-24 Amarin Pharmaceuticals Ireland Limited Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy
US9814733B2 (en) 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en) 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
AU2014203179C1 (en) 2013-06-14 2017-05-04 Aker Biomarine Antarctic As Lipid extraction processes
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
GB201400431D0 (en) 2014-01-10 2014-02-26 Aker Biomarine As Phospholipid compositions and their preparation
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
WO2015195662A1 (en) 2014-06-16 2015-12-23 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids
PL3256003T5 (en) 2015-02-11 2025-11-17 Aker Biomarine Human Ingredients As Lipid extraction processes
NZ747847A (en) 2015-02-11 2023-06-30 Aker Biomarine Antarctic As Lipid compositions
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
WO2018213663A1 (en) 2017-05-19 2018-11-22 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject having reduced kidney function
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
EP3700518A4 (en) 2018-09-24 2020-12-16 Amarin Pharmaceuticals Ireland Limited METHODS FOR REDUCING THE RISK OF CARDIOVASCULAR EVENTS IN A SUBJECT
CN114980973A (en) 2019-11-12 2022-08-30 阿马里纳药物爱尔兰有限公司 Method for reducing the risk of cardiovascular events in a subject with atrial fibrillation and/or atrial flutter
EP4326244A4 (en) 2021-04-21 2025-03-19 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3863678D1 (en) * 1987-04-27 1991-08-22 Efamol Holdings PHARMACEUTICAL PREPARATIONS CONTAINING LITHIUM SALTS.
US5252333A (en) * 1987-04-27 1993-10-12 Scotia Holdings Plc Lithium salt-containing pharmaceutical compositions
JPH08511533A (en) * 1993-06-09 1996-12-03 マーテック・バイオサイエンスィズ・コーポレーション Methods and pharmaceutical compositions useful in the treatment of neurological disorders

Also Published As

Publication number Publication date
WO1997039759A3 (en) 1998-01-15
WO1997039759A2 (en) 1997-10-30

Similar Documents

Publication Publication Date Title
AU2738497A (en) Omega-3 fatty acids and omega-3 phosphatidylcholine in the treatment of bipolar disorder
ZA971082B (en) Azabicyclic esters of carbamic acids useful in therapy.
HUP0300236A3 (en) Use of polyunsaturated fatty acids for reducing the incidence of necrotizing enterocolitis and process for their preparation
EP0736545A3 (en) Dextrin ester of fatty acids and use thereof
DE69506642D1 (en) Pharmaceutical preparations containing polyunsaturated fatty acids together with antioxidant vitamins and provitamins
AU1894297A (en) Highly branched polyamidoamines and their preparation
AU4028395A (en) Cosmetic or dermatological composition in the form of a water-in-oil emulsion with a high content of hydroxy acids
AU4342989A (en) Mercapto-acylamino acids useful in the treatment of cardiovascular disorders and as analgesics
AU1642395A (en) Alpha-aminoalkanoic acids and reduction products
AU2003217759A1 (en) Omega-3 fatty acids or omega-3 phosphatidylcholine in the treatment of depression
AU2111095A (en) Salts of omega-3-polyunsaturated fatty acids and pharmaceutical formulations containing them
AU5836498A (en) N-acyl-hydroxyamino acid esters and their use
AU2619797A (en) Silyl-linked polyamidoamines and their preparation
AUPQ480399A0 (en) Unsaturated fatty acids and their uses in therapy
AU4130597A (en) Use of essential fatty acids for the treatment and prevention of radiation damage to erythrocytes
IL123421A0 (en) Phenylacetic acids their preparation and compositions comprising them
AU4215997A (en) Esters of unsaturated fatty acids
PL332853A1 (en) Method of obtaining alpha-alkoxy-alpha-trifluoromethyl-acrylacetic esters and acids
ZA971405B (en) Skin treatment with salicylic acid esters and retinoids
IL120903A0 (en) Fluoroalkylglycosiduronic acids and corresponding 6(3)-lactones their preparation and their uses
HK1032203A (en) Choline esters of fatty acids and their use in the treatment of stroke
ZA9510120B (en) Iminooxybenzylcrotonate esters their preparation and their use
AUPM677894A0 (en) Modified fatty acids in the treatment of inflammation
AUPM878194A0 (en) Modified fatty acids in the treatment of inflammation
EP0792878A3 (en) Geminal carboxylic acids and esters thereof, pharmaceutical formulations containing them useful in the treatment of bone dysmetabolism